IL281043A - Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry - Google Patents

Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry

Info

Publication number
IL281043A
IL281043A IL281043A IL28104321A IL281043A IL 281043 A IL281043 A IL 281043A IL 281043 A IL281043 A IL 281043A IL 28104321 A IL28104321 A IL 28104321A IL 281043 A IL281043 A IL 281043A
Authority
IL
Israel
Prior art keywords
compounds
methods
vasculogenic mimicry
inhibiting vasculogenic
receptors
Prior art date
Application number
IL281043A
Other languages
English (en)
Hebrew (he)
Original Assignee
Transfert Plus Sec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transfert Plus Sec filed Critical Transfert Plus Sec
Publication of IL281043A publication Critical patent/IL281043A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/083Neurotensin
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL281043A 2018-08-24 2021-02-23 Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry IL281043A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862722726P 2018-08-24 2018-08-24
US201962804063P 2019-02-11 2019-02-11
PCT/CA2019/051170 WO2020037434A1 (en) 2018-08-24 2019-08-26 Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry

Publications (1)

Publication Number Publication Date
IL281043A true IL281043A (en) 2021-04-29

Family

ID=69591094

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281043A IL281043A (en) 2018-08-24 2021-02-23 Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry

Country Status (8)

Country Link
US (1) US20220000971A1 (https=)
EP (1) EP3844190A4 (https=)
JP (1) JP7592320B2 (https=)
CN (1) CN113286820B (https=)
AU (1) AU2019324747A1 (https=)
CA (1) CA3110414A1 (https=)
IL (1) IL281043A (https=)
WO (1) WO2020037434A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107708733B (zh) 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
CA3006313C (en) 2015-11-24 2020-02-11 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
TWI809147B (zh) 2018-07-13 2023-07-21 美商阿列克特有限責任公司 抗分揀蛋白抗體及其使用方法
CN116731113A (zh) * 2022-03-01 2023-09-12 上海智肽生物科技有限公司 针对sort1的多肽化合物及其药物偶联物
CN119403786A (zh) 2022-06-23 2025-02-07 德罗普尼尔生物有限公司 选择性诱导细胞外靶标在溶酶体中降解的双功能分子
CN120641133A (zh) * 2022-11-14 2025-09-12 瑟瑞技术公司 用于刺激抗肿瘤免疫应答的药物缀合物化合物
WO2025054707A1 (en) * 2023-09-11 2025-03-20 Theratechnologies Inc. Peptide conjugates of camptothecin analogs and uses thereof
WO2025208212A1 (en) * 2024-04-02 2025-10-09 Theratechnologies Inc. Combination therapies comprising peptide-drug conjugates targeting sortilin
WO2025236098A1 (en) * 2024-05-16 2025-11-20 Theratechnologies Inc. Peptide conjugates of maytansinoids and uses thereof
WO2026021513A1 (zh) * 2024-07-25 2026-01-29 上海湃鸿生物科技有限公司 一种多肽药物偶联物及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016270874B2 (en) * 2015-06-03 2018-12-06 Tairx, Inc. Novel use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry
CA3006313C (en) * 2015-11-24 2020-02-11 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy

Also Published As

Publication number Publication date
JP2021535209A (ja) 2021-12-16
CN113286820B (zh) 2025-04-08
JP7592320B2 (ja) 2024-12-02
AU2019324747A1 (en) 2021-04-01
WO2020037434A1 (en) 2020-02-27
CN113286820A (zh) 2021-08-20
EP3844190A4 (en) 2022-06-08
CA3110414A1 (en) 2020-02-27
EP3844190A1 (en) 2021-07-07
US20220000971A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
IL281043A (en) Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry
SG11202106520VA (en) Kif18a inhibitors
IL304835A (en) Oxadiazole trp channel inhibitors
PT3814341T (pt) Inibidores de recetor erbb
IL277006A (en) CD73 inhibitors
IL276813A (en) Arginase inhibitors
IL304348A (en) cd73 inhibitors
SG11202105711SA (en) Rnai constructs for inhibiting pnpla3 expression
IL277970A (en) Compounds and Methods for Reducing FXI Expression
IL281815A (en) VAP-1 inhibitors
IL276013A (en) pi4kiiibeta inhibitors
SG11202103776YA (en) Apparatus for delivery of radioembolization microspheres
IL283627A (en) Improved transport of large materials
SG11202102379XA (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
GB2581127B (en) Protection apparatus
ZA202101964B (en) Combustion apparatus
GB201817672D0 (en) Combustion effect apparatus
HK40052673A (en) Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry
PL3643704T3 (pl) Nowe produkty pośrednie do wytwarzania chlorowodorku remifentanilu
IL284752A (en) Cb1r receptor blockers with acyclic backbones
GB201908044D0 (en) Dopamine-B-Hydroxylase inhibitors
GB201812462D0 (en) Inhibitors
GB201910526D0 (en) Antagonist
GB201909500D0 (en) Antagonist
GB201905476D0 (en) MAPA4K4 Inhibitors